MiMedx Group’s (MDXG) Market Outperform Rating Reaffirmed at Citizens Jmp

Citizens Jmp reiterated their market outperform rating on shares of MiMedx Group (NASDAQ:MDXG) in a research note issued to investors on Monday,Benzinga reports. Citizens Jmp currently has a $7.00 target price on the stock, down from their prior target price of $10.00.

A number of other analysts have also commented on MDXG. Wall Street Zen lowered MiMedx Group from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 28th. Citigroup initiated coverage on MiMedx Group in a research note on Monday, February 23rd. They set a “market outperform” rating on the stock. UBS Group set a $10.00 price objective on MiMedx Group in a research note on Monday, February 23rd. Craig Hallum decreased their price objective on MiMedx Group from $10.00 to $7.00 and set a “buy” rating on the stock in a research note on Friday. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of MiMedx Group in a research note on Monday, December 29th. Six analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $8.67.

MiMedx Group Stock Performance

NASDAQ:MDXG opened at $3.25 on Monday. The company has a current ratio of 4.32, a quick ratio of 3.92 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $482.85 million, a P/E ratio of 10.16 and a beta of 1.65. MiMedx Group has a twelve month low of $3.20 and a twelve month high of $7.99. The firm has a 50-day moving average price of $4.42 and a two-hundred day moving average price of $5.82.

MiMedx Group (NASDAQ:MDXG) last posted its quarterly earnings data on Wednesday, February 25th. The company reported $0.14 EPS for the quarter, beating analysts’ consensus estimates of $0.09 by $0.05. The business had revenue of $118.10 million for the quarter, compared to analyst estimates of $106.78 million. MiMedx Group had a return on equity of 29.37% and a net margin of 11.60%. As a group, research analysts expect that MiMedx Group will post 0.12 earnings per share for the current fiscal year.

Hedge Funds Weigh In On MiMedx Group

Several large investors have recently added to or reduced their stakes in MDXG. Royal Bank of Canada lifted its position in MiMedx Group by 1.4% during the first quarter. Royal Bank of Canada now owns 982,532 shares of the company’s stock worth $7,466,000 after buying an additional 13,629 shares during the period. AQR Capital Management LLC lifted its position in MiMedx Group by 42.6% during the first quarter. AQR Capital Management LLC now owns 14,374 shares of the company’s stock worth $109,000 after buying an additional 4,296 shares during the period. Jacobs Levy Equity Management Inc. purchased a new position in MiMedx Group during the first quarter worth about $232,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in MiMedx Group by 5.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 73,518 shares of the company’s stock worth $559,000 after buying an additional 4,049 shares during the period. Finally, Millennium Management LLC lifted its position in MiMedx Group by 93.9% during the first quarter. Millennium Management LLC now owns 1,230,984 shares of the company’s stock worth $9,355,000 after buying an additional 596,016 shares during the period. 79.15% of the stock is currently owned by hedge funds and other institutional investors.

About MiMedx Group

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.